Hidenori Hirukawa

Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study

Tomoe Kinoshita, Masashi Shimoda, Koji Nakashima et al. · Journal of Diabetes Investigation · 2020 · 102 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice

Seizo Okauchi, Masashi Shimoda, Atsushi Obata et al. · Biochemical and Biophysical Research Communications · 2015 · 62 citations

Medicine, Endocrinology, Pharmacology +17

Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes

Tomohiko Kimura, Hideaki Kaneto, Masashi Shimoda et al. · Molecular and Cellular Endocrinology · 2014 · 59 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β‐cells in <i>db/db</i> mice: The earlier and longer, the better

Tomohiko Kimura, Atsushi Obata, Masashi Shimoda et al. · Diabetes Obesity and Metabolism · 2018 · 52 citations

Medicine, Endocrinology, Pharmacology +17

Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus

Shinji Kamei, Masahiro Iwamoto, Miyuki Kameyama et al. · Journal of Diabetes Research · 2018 · 39 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17